Nabil Hajji, BSc, MRes, PGcert, PhD
Chief Scientific Officer (CSO)
Dr Nabil Hajji’s is a doctor at the Centre of Pharmacology and Therapeutics, Department of medicine in the department of Medicine at Imperial College London. NH got his PhD in Molecular Oncology at Seville University.
Currently NH is lecturer in epigenetics and translational oncology with a strong expertise and track record in the mechanisms of epigenetics alteration in cancer, mitochondrial and apoptosis pathways. NH over the last few years has established the mechanism behind classical anticancer treatment resistance of several types of cancer, which is related to deficiencies in the epigenetic mechanism that control apoptotic machinery. NH focuses on epigenetics and drug resistance research.
He examines how epigenetic alteration leads to tumors resistance to chemotherapy and used approaches to improving treatment by overcoming drug resistance. NH research area of interest and expertise also includes different aspects of epigenetic alterations as biomarkers of drug resistance.
NH developed In vivo Imaging of Epigenetic Biomarkers for Cancer Chemoresistance: Towards More Effective Personalized Treatments in Cancer.
His recent discovery work at Imperial College London (in the journal JCI) reached clinical trial Phase I.
He developed outstanding research programs culminating in research funding and major publications as first and corresponding author in a leading journal.